Kim Kamdar

Kim earned her BA from Northwestern University and her PhD from Emory University.

Kim Kamdar, Ph.D. is a Managing Partner with Medical Excellence Capital. Kim has been involved in cutting edge therapeutic start-ups and companies with promising molecular and companion diagnostics to support personalized medicine for over 20 years. Kim has helped to create and served on the board of over a dozen companies. She was the Founding CEO for Truvian Health, Aspen Neuroscience and Obalon Therapeutics (NASDAQ: OBLN). Kim has also helped to create Seraphina Therapeutics and currently serves as Chair.   She was an early investor and helped to create companies including Syndax Pharmaceuticals (NASDAQ: SNDX), and Singular Genomics (NASDAQ: OMIC).  Additional investments and BOD memberships include Alume Biosciences, DHI, Recellience 15, Savanna, Trotana, ClicBio, and Sera Prognostics (NASDAQ: SERA).

Kim has been part of Domain Associates since 2005 and a Partner since 2010. Prior to Domain, Kim was a Kauffman Fellow at MPM Capital. Prior to that, she was a research director at Novartis, where she built and led a research team that focused on the biology, genetics and genomics of model organisms. Kim is the author of ten papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and cell biology from Emory University.

​

Kim is currently an Advisory Board Member for Dr. Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine and a Board Member at the La Jolla Institute of Immunology. 

​

Kim served her fellowship as a member of Class 8 under mentor Nick Galakatos at MPM Capital in Boston, MA.